Philippe Andre Gallay

US Patent:

56058020, Feb 25, 1997

Filed:

Sep 30, 1994

Appl. No.:

8/316038

Inventors:

Didier P. Trono - Solana Beach CA
Christopher R. Aiken - Encinitas CA
Simon M. Swingler - San Diego CA
Philippe A. Gallay - Solana Beach CA

Assignee:

The Salk Institute for Biological Studies - La Jolla CA

International Classification:

G01N 33569

US Classification:

435 74

Abstract:

In accordance with the present invention, there are provided novel assays which allow the identification of compounds which block the ability of lentiviruses to infect non-dividing cells. Compounds discovered employing the invention methods can be employed to block the ability of HIV to infect non-dividing cells. In accordance with another aspect of the present invention, novel antibodies have been developed which are specifically immunoreactive with the phosphorylated form of HIV-1 MA. In accordance with yet another aspect of the present invention, novel kinases which phosphorylate HIV-1 MA have been discovered.

US Patent:

60135166, Jan 11, 2000

Filed:

Oct 6, 1995

Appl. No.:

8/540259

Inventors:

Inder Verma - Solana Beach CA
Didier Trono - San Diego CA
Luigi Naldini - Del Mar CA
Philippe Gallay - Solana Beach CA

Assignee:

The Salk Institute for Biological Studies - La Jolla CA

International Classification:

C12N 1500

US Classification:

435325

Abstract:

A recombinant retrovirus capable of infecting a non-dividing cell and a method of producing such a virus is provided. The recombinant retrovirus is preferably of lentivirus origin and is useful for the treatment of a variety of disorders including neurological disorders and disorders of other non-dividing cells.

US Patent:

20140328795, Nov 6, 2014

Filed:

Sep 10, 2013

Appl. No.:

14/023437

Inventors:

Zhilei Chen - College Station TX, US
Rudo Simeon - College Station TX, US
Michael Bobardt - La Jolla CA, US
Philippe Gallay - La Jolla CA, US

Assignee:

The Texas A&M University System - College Station TX
The Scripps Research Institute - La Jolla CA

International Classification:

A61K 31/542
A61K 45/06

US Classification:

424 854, 5142245, 514 43, 435238

Abstract:

In an embodiment of the present disclosure there is provided a method of inactivating enveloped DNA virus particles in a biological sample. In an embodiment, such a method comprises contacting the biological sample with an effective amount of an antiviral composition comprising PD 404,182 In some embodiments, the DNA virus is the Herpes Simplex virus-1 (HSV-1) or the Herpes Simplex Virus-2 (HSV-2). In another embodiment of the present disclosure, there is provided a method of treating, preventing, or reducing a viral infection caused by an enveloped DNA virus in a subject in need thereof. In yet another embodiment, there is provided a method of preventing transmission of a viral infection to a subject in need thereof. In an embodiment, such a method comprises contacting a mucus membrane of the subject with a topical formulation comprising an effective amount of PD 404,182 in combination with a pharmaceutically acceptable carrier

US Patent:

20140227335, Aug 14, 2014

Filed:

Sep 10, 2013

Appl. No.:

14/023434

Inventors:

Zhilei Chen - College Station TX, US
Rudo Simeon - College Station TX, US
Michael Bobardt - La Jolla CA, US
Philippe Gallay - La Jolla CA, US

International Classification:

A61K 31/542
A61K 45/06

US Classification:

424422, 5142245, 424 854, 435238

Abstract:

In some embodiments the present disclosure provides a method of inactivating a RNA virus of the family retroviridae in a biological sample. Such a method comprises contacting the biological sample with an effective amount of an antiviral composition comprising PD 404,182. In an embodiment of the present disclosure the RNA virus is selected from the group consisting of HIV pseudotyped lentiviruses, primary human immunodeficiency virus-1 isolates (HIV-1), human immunodeficiency virus-2 (HIV-2), and simian immunodeficiency virus (SIV). Further embodiments of the present disclosure pertain to a method of treating a subject infected by a RNA virus of the family retroviridae. Another embodiment of the present invention pertains to a method of preventing transmission of a RNA virus of the family retroviridae in a subject in need thereof.